Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.

Foth M, Ahmad I, van Rhijn BW, van der Kwast T, Bergman AM, King L, Ridgway R, Leung HY, Fraser S, Sansom OJ, Iwata T.

J Pathol. 2014 Jun;233(2):148-58. doi: 10.1002/path.4334. Epub 2014 Mar 31.

2.

PI3K/AKT pathway activation in bladder carcinogenesis.

Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y.

Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24.

3.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

4.

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

di Martino E, L'Hôte CG, Kennedy W, Tomlinson DC, Knowles MA.

Oncogene. 2009 Dec 3;28(48):4306-16. doi: 10.1038/onc.2009.280. Epub 2009 Sep 14.

5.

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S.

Hum Pathol. 2012 Oct;43(10):1573-82. doi: 10.1016/j.humpath.2011.10.026. Epub 2012 Mar 12.

PMID:
22417847
6.

Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.

Qian CN, Furge KA, Knol J, Huang D, Chen J, Dykema KJ, Kort EJ, Massie A, Khoo SK, Vanden Beldt K, Resau JH, Anema J, Kahnoski RJ, Morreau H, Camparo P, Comperat E, Sibony M, Denoux Y, Molinie V, Vieillefond A, Eng C, Williams BO, Teh BT.

Cancer Res. 2009 Nov 1;69(21):8256-64. doi: 10.1158/0008-5472.CAN-09-1689. Epub 2009 Oct 20.

7.

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.

Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O.

Br J Cancer. 2013 Sep 17;109(6):1586-92. doi: 10.1038/bjc.2013.505. Epub 2013 Aug 29.

8.

FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.

Du X, Wang QR, Chan E, Merchant M, Liu J, French D, Ashkenazi A, Qing J.

Cancer Res. 2012 Nov 15;72(22):5843-55. doi: 10.1158/0008-5472.CAN-12-1329. Epub 2012 Sep 26.

9.

Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.

Tsuruta H, Kishimoto H, Sasaki T, Horie Y, Natsui M, Shibata Y, Hamada K, Yajima N, Kawahara K, Sasaki M, Tsuchiya N, Enomoto K, Mak TW, Nakano T, Habuchi T, Suzuki A.

Cancer Res. 2006 Sep 1;66(17):8389-96.

10.

Fibroblast growth factor receptor-3 in urothelial tumorigenesis.

Iyer G, Milowsky MI.

Urol Oncol. 2013 Apr;31(3):303-11. doi: 10.1016/j.urolonc.2011.12.001. Epub 2012 Jan 30. Review.

PMID:
22285006
11.

No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.

Otto W, Denzinger S, Bertz S, Gaumann A, Wild PJ, Hartmann A, Stoehr R.

Int J Cancer. 2009 Nov 1;125(9):2205-8. doi: 10.1002/ijc.24598.

12.

β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.

Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, Patel S, Woodgett J, Winton DJ, Taketo MM, Wu XR, Leung HY, Sansom OJ.

Oncogene. 2011 Jan 13;30(2):178-89. doi: 10.1038/onc.2010.399. Epub 2010 Sep 6.

13.

Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium.

Røtterud R, Fosså SD, Nesland JM.

Histol Histopathol. 2007 Apr;22(4):349-63. doi: 10.14670/HH-22.349.

PMID:
17290345
14.

Sleeping beauty: awakening urothelium from its slumber.

Balsara ZR, Li X.

Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F732-F743. doi: 10.1152/ajprenal.00337.2016. Epub 2017 Jan 25. Review.

PMID:
28122714
15.

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

Rebouissou S, Hérault A, Letouzé E, Neuzillet Y, Laplanche A, Ofualuka K, Maillé P, Leroy K, Riou A, Lepage ML, Vordos D, de la Taille A, Denoux Y, Sibony M, Guyon F, Lebret T, Benhamou S, Allory Y, Radvanyi F.

J Pathol. 2012 Jul;227(3):315-24. doi: 10.1002/path.4017. Epub 2012 May 8.

PMID:
22422578
16.

Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner.

Yoo LI, Liu DW, Le Vu S, Bronson RT, Wu H, Yuan J.

Cancer Res. 2006 Feb 15;66(4):1929-39.

17.

Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.

Quattrone A, Wozniak A, Dewaele B, Floris G, Vanspauwen V, Van Looy T, Schöffski P, Rutkowski P, Sciot R, Debiec-Rychter M.

Mod Pathol. 2014 Nov;27(11):1510-20. doi: 10.1038/modpathol.2014.53. Epub 2014 Apr 18.

18.

[Current knowledge in molecular pathology of urothelial cancer].

Knüchel-Clarke R, Dahl E, Gaisa NT, Schwamborn K, Lindemann-Docter K, Henkel C.

Pathologe. 2010 Oct;31 Suppl 2:234-8. doi: 10.1007/s00292-010-1324-z. Review. German.

PMID:
20665023
19.

Deregulation of Rab and Rab effector genes in bladder cancer.

Ho JR, Chapeaublanc E, Kirkwood L, Nicolle R, Benhamou S, Lebret T, Allory Y, Southgate J, Radvanyi F, Goud B.

PLoS One. 2012;7(6):e39469. doi: 10.1371/journal.pone.0039469. Epub 2012 Jun 19.

Supplemental Content

Support Center